Dipeptide apoptosis inhibitors and the use thereof

Details Dipeptide apoptosis inhibitors and the use thereof Dipeptide apoptosis inhibitors and the use thereof

2005-09-27

2005-09-27

Celsa, Bennett (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S885000, C560S169000, C560S171000

Reexamination Certificate

active

06949516

ABSTRACT:
The present invention is directed to novel dipeptides thereof, represented by the general Formula I:where R1-R3and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

REFERENCES:
patent: 4153688 (1979-05-01), Dimicoli et al.
patent: 4518528 (1985-05-01), Rasnick
patent: 5416013 (1995-05-01), Black et al.
patent: 5430128 (1995-07-01), Chapman et al.
patent: 5434248 (1995-07-01), Chapman et al.
patent: 5462939 (1995-10-01), Dolle et al.
patent: 5585357 (1996-12-01), Dolle et al.
patent: 5677283 (1997-10-01), Dolle et al.
patent: 5756465 (1998-05-01), Sleath et al.
patent: 5843904 (1998-12-01), Bemis et al.
patent: 5866545 (1999-02-01), Hagmann et al.
patent: 5869519 (1999-02-01), Karanewsky et al.
patent: 5877197 (1999-03-01), Karanewsky et al.
patent: 5932549 (1999-08-01), Allen et al.
patent: 6136787 (2000-10-01), Black et al.
patent: 6153591 (2000-11-01), Cai et al.
patent: 6184244 (2001-02-01), Karanewsky et al.
patent: 6197750 (2001-03-01), Karanewsky et al.
patent: 6242422 (2001-06-01), Karanewsky et al.
patent: 6355618 (2002-03-01), Cai et al.
patent: 6495522 (2002-12-01), Wang et al.
patent: 6515173 (2003-02-01), Ternansky et al.
patent: 6525024 (2003-02-01), Ternansky et al.
patent: 6544951 (2003-04-01), Karanewsky et al.
patent: 6566338 (2003-05-01), Weber et al.
patent: 6573259 (2003-06-01), Golec et al.
patent: 2002/0042376 (2002-04-01), Karanewsky et al.
patent: 2002/0137686 (2002-09-01), Ternansky et al.
patent: 2003/0232788 (2003-12-01), Karanewsky et al.
patent: 0 519 748 (1992-12-01), None
patent: 0 618 223 (1994-10-01), None
patent: WO 91/15577 (1991-10-01), None
patent: WO 93/05071 (1993-03-01), None
patent: WO 96/03982 (1996-02-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 98/10778 (1998-03-01), None
patent: WO 98/11109 (1998-03-01), None
patent: WO 98/41232 (1998-09-01), None
patent: WO 99/18781 (1999-04-01), None
patent: WO 99/47154 (1999-09-01), None
Alnemri, E.S. et al., “Human ICE/CED-3 Protease Nomenclature,”Cell 87:171, Cell Press, Cambridge, MA (1996).
An, S., and Knox, K.A., “Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP,”FEBS Lett. 386:115-122, Elsevier Science Publishers B.V., Amsterdam (1996).
Angliker, H., et al., “The synthesis of lysylfluoromethanes and their properties as inhibitors of trypsin, plasmin and cathepsin B,”Biochem. J. 241:871-875, The Biochemical Society, London, England (1987).
Black, R.A. et al., A Pre-aspartate-specific Protease from Human Leukocytes That Cleaves Pro-interleukin-2α,J. Biol. Chem. 264:5323-5326, The American Society for Biochemistry and Molecular Biology, Baltimore, MD (1989).
Black, S.C. et al., “Co-localization of the Cysteine Protease Caspase-3 with Apoptotic Myocytes after In Vivo Myocardial Ischemia and Reperfusion in the Rat,”J. Mol. Cell. Cardiol. 30:733-742, Academic Press, Inc., New York, NY (Apr. 1998).
Bourne, E.J. et al., “Studies of Trifluoroacetic Acid. Part XVIII. Reaction of N-Aroylglycines with Perfluoro-carboxylic Anhydrides.”J. Chem. Soc. Part II:1771-1775, The Chemical Society, London, England (1961).
Conaldi, P.G. et al., “HIV-1 Kills Renal Tubular Epithelial Cells In Vitro by Triggering an Apoptotic Pathway Involving Caspase Activation and Fas Upregulation,”J. Clin. Invest. 102:2041-2049, The American Society for Clinical Investigation, Inc., New York, NY (Dec. 1998).
del Pozo, O., and Lam, E., “Caspases and programmed cell death in the hypersensitive response of plants to pathogens,”Curr. Biol. 8:1129-1132, Current Biology Ltd., London, England (Oct. 1998).
di Giovine, F.S., and Duff, G.W., “Interleukin 1: the first interleukin,”Immunology Today 11:13-14, Elsevier Science Publishers Ltd., Barking, England (1990).
Dinarello, C. A., “Interleukin-1 and Interleukin-1 Antagonism,”Blood 77:1627-1652, American Society for Hematology, Philadelphia, PA (1991).
Dolle, R.E. et al., “P1Aspartate-Based Peptide α-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1β-Converting Enzyme,”J. Med. Chem. 37:563-564, American Chemical Society, Washington, DC (1994).
Dolle, R.E. et al., “Aspartyl α-((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1β Converting Enzyme Inhibitors. Significance of the P1and P3Amido Nitrogens for Enzyme-Peptide Inhibitor Binding,”J. Med. Chem. 37:3863-3866, American Chemical Society, Washington, DC (1994).
Dolle, R.E. et al., “Aspartyl α-((Diphenylphosphinyl)oxy)methyl Ketones as Novel Inhibitors of Interleukin-1β Converting Enzyme. Utility of the Diphenylphosphinic Acid Leaving Group for the Inhibition of Cysteine Proteases,”J. Med. Chem. 38:220-222, American Chemical Society, Washington, DC (1995).
Ellis, R.E. et al., “Mechanisms and Functions of Cell Death,”Ann. Rev. Cell Biol. 7:663-698, Annual Reviews, Palo Alto, CA (1991).
Emery, E. et al., “Apoptosis after traumatic human spinal cord injury,”J. Neurosurg. 89:911-920, American Association of Neurological Surgeons, Charlottesville, VA (Dec. 1998).
Goldberg, Y.P. et al., “Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract,”Nature Genetics 13:442-449, Nature Publishing Co., New York, NY (1996).
Graybill, T.L. et al., “α-((Tetronoyl)oxy)- and α-((Tetramoyl)oxy)methyl Ketone Inhibitors of the Interleukin-1β Converting Enzyme (ICE),”Bioorg. Med. Chem. Lett. 7:41-46, Elsevier Science Ltd., Oxford, England (1997).
Greenberg, J.T. et al., “Programmed Cell Death in Plants: A Pathogen-Triggered Response Activated Coordinately with Multiple Defense Functions,”Cell 77:551-563, Cell Press, Cambridge, MA (1994).
Grobmyer, S.R. et al., “Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock,”Mol. Med. 5:585-594, Johns Hopkins University Press, Baltimore, MD (Sep. 1999).
Hara, H. et al., “Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage,”Proc. Natl. Acad. Sci. USA 94:2007-2012, National Academy of Sciences, Washington, DC (Mar. 1997).
Hiraoka, J. et al., “Participation of apoptosis in renal amyloidosis,”Jpn. J. Nephrol. 40:276-283, Japanese Society of Nephrology, Tokyo, Japan (May 1998).
Hotchkiss, R.S. et al., “Prevention of lymphocyte cell death in sepsis improves survival in mice,”Proc. Natl. Acad. Sci. USA 96:14541-14546, National Academy of Sciences, Washington, DC (Dec. 1999).
Jaeschke, H. et al., “Activation of Caspase 3 (CPP32)-Like Proteases Is Essential for TNF-α-Induced Hepatic Parenchymal Cell Apoptosis and Neutrophil-Mediated Necrosis in a Murine Endotoxin Shock Model,”J. Immun. 160:3480-3486, American Association of Immunologists, Baltimore, MD (Apr. 1998).
Jones, R.A. et al., “Fas-Mediated Apoptosis in Mouse Hepatocytes Involves the Processing and Activation of Caspases,”Hepatology 27:1632-1642, American Association for the Study of Liver Diseases, Philadelphia, PA (Jun. 1998).
Kermer, P. et al., “Inhibition of CPP32-Like Proteases Rescues Axotomized Retinal Ganglion Cells from Secondary Cell Death In Vivo,”J. Neuroscience 18:4656-4662, Society for Neuroscience, Washington, DC (Jun. 1998).
Kubo, S. et al., “Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors,”Proc. Natl. Acad. Sci. USA 95:9552-9557,

Affiliated with

Also associated with

Rating

Dipeptide apoptosis inhibitors and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dipeptide apoptosis inhibitors and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptide apoptosis inhibitors and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3412826